Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients
-
Published:2021-08
Issue:4
Volume:60
Page:103159
-
ISSN:1473-0502
-
Container-title:Transfusion and Apheresis Science
-
language:en
-
Short-container-title:Transfusion and Apheresis Science
Author:
Sarıcı AhmetORCID,
Erkurt Mehmet Ali,
Bahçecioğlu Ömer FarukORCID,
Gök SelimORCID,
Kuku İrfan,
Biçim Soykan,
Berber İlhami,
Kaya Emin,
Özgül Mustafa
Reference24 articles.
1. CA Cancer;Siegel,2012
2. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review;Hahn;Biol Blood Marrow Transplant,2003
3. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med,2017
4. Poor mobilization of hematopoietic stem cells—definitions, incidence, risk factors, and impact on outcome of autologous transplantation;Wuchter;Biol Blood Marrow Transplant,2010
5. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100);Giralt;Leukemia,2009
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献